Research programme: granulocyte colony-stimulating factor - Bolder BioTechnology

Drug Profile

Research programme: granulocyte colony-stimulating factor - Bolder BioTechnology

Alternative Names: BBT-018; G-CSF - Bolder BioTechnology; Long-acting G-CSF - Bolder BioTechnology; PEG-G-CSF - Bolder BioTechnology; PEG-granulocyte colony stimulating factor - Bolder BioTechnology

Latest Information Update: 09 Nov 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Bolder BioTechnology
  • Class Granulocyte colony-stimulating factors; Polyethylene glycols
  • Mechanism of Action Immunomodulators; Neutrophil stimulants; Stem cell stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Neutropenia; Radiation injuries

Most Recent Events

  • 09 Nov 2010 Preclinical development in Neutropenia and Radiation injuries is ongoing in USA
  • 03 Nov 2010 Bolder BioTechnology receives a Qualifying Therapeutic Discovery Project (QTDP) grant from the US Department of Health and Human Services for BBT 015 development in Radiation injuries and Neutropenia
  • 17 Sep 2009 Bolder BioTechnology receives SBIR grant from National Institute of Allergy and Infectious Disease for Long acting G-CSF development in Acute radiation syndrome
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top